Medigene participates at four conferences in October

Martinsried/Munich – Medigene AG (FSE: MDG1, Prime Standard, SDAX) today announced its participation at the following upcoming investor and scientific conferences:

Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Date: 30 September – 03 October 2018
Location: New York, USA

European Society of Gene and Cell Therapy (ESGCT) Annual Congress
Date: 16 – 19 October 2018
Location: Lausanne, Switzerland

ESMO – European Society for Medical Oncology Congress
Date: 19 – 23 October 2018
Location: Munich, Germany

BTIG Healthcare Conference
Date: 25 October 2018
Location: New York, USA

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, SDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 – 89 – 20 00 33 – 33 01,